Similar benefits of these combination therapies were observed in several KRAS-driven models, including the colorectal cancer model CT-26, the NSCLC model KPAR and the PDAC model EPP2 (Extended Data Fig. 11f–n). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.